Curis, Inc.~ Nasdaq Bio~ CRIS due diligence

Curis, Inc.~ Nasdaq Bio~ CRIS due diligence

CRIS Company Overview & Description

Curis, Inc is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at http://www.curis.com

CRIS Corporate Fact Sheet: http://www.curis.com/Corp_Fact_Sheet_2011.pdf

CRIS Corporate Overview Presentation: http://www.curis.com/Corporate_Overview.pdf

CRIS Key Company Management

Daniel R. Passeri
President and Chief Executive Officer
Mr. Passeri has served as our President and Chief Executive Officer and as a director since September 2001. From November 2000 to September 2001, Mr. Passeri served as Senior Vice President, Corporate Development and Strategic Planning of the Company. From March 1997 to November 2000, Mr. Passeri was employed by GeneLogic Inc., a biotechnology company, most recently as Senior Vice President, Corporate Development and Strategic Planning. From February 1995 to March 1997, Mr. Passeri was employed by Boehringer Mannheim, a pharmaceutical, biotechnology and diagnostic company, as Director of Technology Management. Mr. Passeri is a graduate of the National Law Center at George Washington University, with a J.D., of the Imperial College of Science, Technology and Medicine at the University of London, with an M.Sc. in biotechnology, and of Northeastern University, with a B.S. in biology.

Maurizio Voi, M.D.
Chief Medical and Chief Development Officer
Dr. Voi has served as our Chief Medical and Chief Development Officer since November 2011. From October 2009 until November 2011, Dr. Voi was employed by Pfizer as Vice President of Clinical Development and Medical Affairs at the Oncology Business Unit of Pfizer’s Global Research and Development site in New York. Dr. Voi joined Pfizer as Thoracic Tumor Strategy Team Leader for Oncology. In this role, he was responsible for developing strategic plans for assets within the Pfizer portfolio for the treatment of thoracic cancers, with a special emphasis on identifying patient populations most likely to respond to targeted agents by concurrently developing compounds and diagnostics, including XALKORI® (crizotinib), an ALK inhibitor for the treatment of ALK+ advanced non-small cell lung cancer that was granted FDA approval in 2011. Prior to joining Pfizer, Dr. Voi served from 1998 to 2009 in several key positions at Bristol-Myers Squibb Company, most recently as the Executive Director, Global Clinical Development and Medical Affairs, Oncology, where he was instrumental in the development and regulatory submission and approval of Sprycel® in chronic myelogenous leukemia as well as in supplemental BLA’s of Erbitux® in colorectal, non-small cell lung and head and neck cancers. From 1987-1999, he served in several roles at Eli Lilly and Company, where he was involved in preparing the registration dossier for a regulatory approval filing in non-small cell lung cancer of Gemzar® in Europe as well as ultimately assuming responsibility for Gemzar® worldwide development and commercialization.

Dr. Voi received his medical degree from the University of Padua, School of Medicine Italy and practiced medicine at the General Hospital, Dolo in Venice, Italy.

Michael P. Gray
Chief Operating and Chief Financial Officer
Mr. Gray has served as our Chief Operating Officer and Chief Financial Officer since December 2006. From December 2003 until December 2006, Mr. Gray served as our Vice President of Finance and Chief Financial Officer and served as our Senior Director of Finance and Controller from August 2000 until December 2003. Mr. Gray held financial positions including Controller and de Facto Chief Financial Officer at Reprogenesis, a predecessor biotechnology company, from January 1998 until July 2000. Mr. Gray previously served as an audit professional for the accounting and consulting firm of Ernst & Young, LLP. Mr. Gray is a certified public accountant, holds an M.B.A. from the F.W. Olin Graduate School of Business at Babson College, and has a B.S. in accounting from Bryant College.

Changgeng Qian, Ph.D., M.D.
Senior Vice President, Discovery and Preclinical Development
Dr. Qian joined Curis in 2001. He has over 30 years of academic and industrial experience in drug discovery, including pharmacokinetics, drug metabolism, efficacy evaluation, experimental disease model development and drug safety assessment. Prior to Curis, he played a key role in the discovery of several anti-inflammation, anticancer and CNS drug candidates at CytoMed Inc., LeukoSite Inc., and Millennium Pharmaceuticals, Inc. He is an inventor on more than 10 issued U.S. patents and over 25 published PCT patents and has authored approximately 30 scientific publications. Dr. Qian earned a Ph.D. in Pharmacology and an M.D. from the Hunan Medical University and has served as a professor of the University since 1992.

Mark Noel
Vice President, Technology Management and Intellectual Property
Mr. Noel has served as our Vice President, Technology Management and Intellectual Property since September 2008. From March 2001 until September 2008, Mr. Noel served as our Vice President, Technology Management and Business Development. From March 2000 to February 2001, Mr. Noel was employed by GeneLogic, as Vice President of Customer Relations. From January 1998 to February 2000, Mr. Noel was employed by GeneLogic as Senior Director of Program Management. From December 1993 to January 1998, Mr. Noel was employed by the National Cancer Institute’s Office of Technology Development (now the Technology Transfer Branch of the NCI Office of Technology and Industrial Relations), where from July 1997 to January 1998, he served as Acting Deputy Director. From February 1989 to November 1993, Mr. Noel worked as a patent agent at Gist Brocades NV, a supplier of ingredients to the pharmaceutical and food sectors. Mr. Noel holds a B.S. from the University of Maryland.

CRIS Contact Info

Curis Inc. Corporate Headquarters
4 Maguire Road
Lexington, MA 02421
Tel: [617] 503-6500
Fax: [617] 503-6501

Website: http://www.curis.com

Email Alert Subscription: http://investors.curis.com/alerts.cfm?

Contact IR
Curis, Inc.
4 Maguire Road
Lexington, MA 02421
Phone: 617-503-6500
E-mail: info@curis.com

CRIS Recent Developments

SEC Filings
http://finance.yahoo.com/q/sec?s=CRIS+SEC+Filings
Competitors
http://finance.yahoo.com/q/co?s=CRIS+Competitors
Industry
http://finance.yahoo.com/q/in?s=CRIS+Industry
Headlines
http://finance.yahoo.com/q/h?s=CRIS+Headlines

Current Corporate Collaborators
Collaborator Program Disease
Genentech (vismodegib) Hedgehog Pathway Inhibitor Cancer
Debiopharm SA (Debio 0932) Debio 0932 (Hsp90 inhibitor; formerly CUDC-305) Cancer
Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.

The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. In September 2011, Genentech completed an NDA submission with the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma. In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute.
http://www.curis.com/collaborations_detail.php?collaborationid=1

Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase I clinical testing.
http://www.curis.com/collaborations_detail.php?collaborationid=7

CRIS Products & Services

Over the past several years, targeted cancer drugs have been considered among the most promising cancer treatments for obtaining a therapeutic effect with less toxicity when compared with traditional chemotherapy, which, in addition to attacking cancerous cells, also tends to attack a broad range of healthy cells. A large body of published data shows cancers to have multiple, intersecting signaling pathways that support survival, growth, and invasion. Targeting only one or two of these pathways with single-targeted agents has generally only led to modest improvements to existing standards-of-care and most cancer patients with solid tumors do not respond in a clinically meaningful manner. Targeting the correct combination of critical signaling pathways within the network of cancer cell signaling pathways could provide a major improvement in outcomes for cancer patients and is an area of intense research and development.

Curis is utilizing medicinal chemistry and biological expertise to develop a series of proprietary targeted cancer drug programs. These programs focus on the development of single-agent drug candidates targeting one or more molecular components within the signaling pathways associated with certain cancers. These programs are primarily focused on developing a number of proprietary, small molecule, single-agent, multi-targeted inhibitor drug compounds. Each proprietary compound is being designed to inhibit biologically- or clinically-validated cancer targets, including, among others, EGFR, Her2, Bcr-Abl tyrosine kinase and phosphatidylinositol-3-kinase (PI3k), in combination with inhibition of HDAC, which is a validated non-kinase cancer target. Curis is also seeking to use this platform to develop proprietary, differentiated, single-agent, single-target drug candidates for cancer indications.

HDAC inhibition is a core component in each of Curis’ multi-targeted inhibitors. Curis believes that HDAC is a promising non-kinase target for cancer therapy, particularly when combined with simultaneous inhibition of certain other targets. There is substantial preclinical evidence of synergistic induction of cancer cell death when HDAC inhibitors are combined with a diverse range of other targeted therapies or standard chemotherapeutic agents, demonstrating that HDAC inhibition may be more broadly effective in the treatment of cancer when integrated with other inhibitory activities.

Currently, there are two Food and Drug Administration, or FDA, approved HDAC inhibitors and several other HDAC-targeted drug candidates in clinical trials for cancer.
In furtherance of the development of Curis’ targeted cancer programs, the Company outsources certain medicinal chemistry and other preclinical functions with contract research organizations in China. Curis has developed these relationships with Chinese providers to support its U.S. operations and Curis is currently engaging approximately 25 chemists in China. Curis’ drug discovery efforts utilize significant medicinal chemistry resources. The Company’s management believes that these relationships have been important to Curis’ efforts to create a broad portfolio of proprietary cancer drugs by generating several classes of compounds for further development in a cost-effective manner.

Curis filed a number of patents including a broad omnibus patent application that covers the drug design concept that is the basis for the multi-targeted cancer programs, as well as numerous species filings relating to specific classes of compounds which Curis believes will constitute novel compositions from a patentability standpoint. Curis expects that it will continue to file additional patent applications covering new compositions in the future.

CUDC-101, Curis’ first drug candidate from our targeted cancer programs, is being designed as a multi-target inhibitor of HDAC, EGFR and Her2 and is currently the subject of a phase Ib expansion clinical trial as well as a Phase I trial in head and neck cancer in combination with radiation and cisplatin. Curis is also developing CUDC-907, a PI3K/HDAC inhibitor and expects that it will submit an IND for this molecule in early 2012. In August, 2009 Curis licensed its first single-agent, single-target inhibitor drug candidate, CUDC-305 (now Debio 0932), an Hsp90 inhibitor to Debiopharm. Curis researchers are continuing to investigate other classes of compounds in an effort to advance additional compounds into clinical development.

Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.

The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. In September 2011, Genentech submitted a New Drug Application (NDA) to the FDA for vismodegib (GDC-0449, RG3616) in advanced basal cell carcinoma and is also conducting a Phase II clinical trial of the molecule in less severe forms of basal cell carcinoma. In addition, there are several additional Phase I and II clinical trials ongoing under a collaboration between Genentech and independent investigators and the National Cancer Institute.

Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Hsp90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently in Phase Ib clinical testing.

Curis also recently selected orally-available PI3K/HDAC inhibitor CUDC-907 as a development candidate and expects to begin Phase I clinical testing with this molecule in early 2012.
Curis has focused most of its internal resources on developing additional small molecule targeted cancer drug candidates. Curis completed a Phase I clinical trial of CUDC-101, a first-in-class inhibitor of EGFR, Her2 and HDAC, in the first half of 2010. The Company also initiated in August 2010 a Phase Ib expansion trial of this molecule in patients with breast, gastric, head and neck, liver and non-small cell lung cancers and in August 2011 initiated a Phase I clinical trial in HPV- locally advanced head and neck cancer in combination with standard-of-care treatment (cisplatin and radiation).

In addition, Curis has several programs that are in various stages of preclinical drug development. Because of the early stages of development of these programs, its ability and that of the Company's collaborators and licensors to successfully complete preclinical and clinical studies of these product candidates, and the timing of completion of such programs, is highly uncertain.

Financial Reporting/Disclosure & Security Details
Shareholders tools: http://investors.curis.com/

CRIS follows under these quidelines on the Nasdaq market tier.

Investigate more @ http://www.otcmarkets.com/stock/CRIS/quote for more due diligence.

Share Structure
Market Cap. (Mil) $336.19
Shares Out (Mil)76.58
Float (Mil)56.84
Share Related information provided by MorningStar, Inc.
Data as of Jan 9, 2012.
Mil=Millions
watch updates here: http://investors.curis.com/financials.cfm

Par Value: .01

Shareholders
Shareholders of Record: 76
Transfer Agent(s)
BNY Mellon Shareowner Services
P.O. Box 358015
85 Challenger Road
Pittsburgh, PA 15252-8015
Phone: 877.810.2248
TA Corporate Website: http://www.bnymellon.com/shareowner/isd

Financial Reporting/Disclosure
Reporting Status: U.S. Registered & Reporting: SEC Filer
OTC Disclosure last 10Q reported Oct 31, 2011 period ending Sept 30, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8212490
OTC Disclosure last 10K reported Mar 8, 2011 period ending Dec 31, 2011
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7783210
CIK: 0001108205
Fiscal Year End: 12/31
OTC Market Tier: Nasdaq

Profile Data
SIC - Industry Classification: CURIS, INC. - SIC # 2836
Sector: HealthCare
Industry: Biotechnology
Incorporated In: DE, USA
Year of Inc:
Employees: 32

Before You Invest - Investigate! Always do your own due diligence
A critical part of the due diligence: Please be aware, that upon completion of in-depth due diligence there is still a risk factor in all forms of investing.

Please note not all company websites are updated on a regular basis so you should use additional content sources to ensure accuracy.

Resources used in this post: otcmarket.com, www.bloomberg.com, www.finance.yahoo.com, CRIS website

(CRIS website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.)

Images by StocksDiva

StocksDiva has not been compensated for these images in this post

Due Diligence by PYCK Global Marketing

http://pyckglobal.blogspot.com/

PYCK Global Marketing has not been compensated for this Due Diligence post

Disclaimer

HRTE ~~Here Enterprises, Inc.

HRTE About

Here Enterprises, Inc is a developer of wind power, our nation's fastest growing renewable energy resource. The Company is engaged in planning, developing, acquiring and operating wind farms in the United States to generate clean, profitable wind energy. Here Enterprises is developing wind energy projects which co-locate wind farms with commercial businesses in order to maximize cashflow for each project.

Here Enterprises has acquired its first development project. Cycle Ranch is located in Floresville, Texas, the state now leading the nation in wind power production. The Company is developing a wind farm on property that hosts an established motocross speedway drawing thousands of fans, spectators and competitors each week.



HRTE Security Details

Here Enterprises,Inc publicly traded on the OTC Market under the symbol, “HRTE”, and within the PK limited market tier.

Visit http://www.otcmarkets.com/stock/HRTE/quote for more information.




HRTE Products & Services





Exclusive to TALON Wind Turbines from A&C Green Energy.

What is Variable Pitch Technology?
This is an advanced technology that, up until NOW, was only available on those huge megawatt systems you might find in major wind farms. Easily stated, this system enables the wind turbine to maintain a constant peak output during times of higher wind.
How does Variable Pitch Technology work?
Each of the Talon's 3 blades have an attached centrifugal hammer that calculates when the generator is turning too quickly. Each blade is then automatically pitched to control the generator rotation speed.
Why is Variable Pitch Technology important?
When another wind turbine reaches its peak power (usually in high wind speeds around 25-30 mph), there is a decline in the power output curve mostly because of either blade design or tail furling. Instead of a decline in power output with increasing wind speeds, the Talon series maintains its maximum power output up to winds of 56 mph, its top working speed.
What does all this mean?
With the increased power output from the Talon wind turbine, you will have more energy to use and more energy bill savings, which means you can afford to leave your new HDTV on all month long!

Different Wind Turbine Types:
Vertical Axis Wind Turbines (VAWT)
These turbines spin around like a record and have their axis running up and down. These systems are good in urban areas where there is a limited amount of space. The drawback to these systems is that the oncoming wind pushes on both sides of the blades, creating an issue of excess drag and decreased performance.

Horizontal Axis Wind Turbines (HAWT)
Like most wind turbines and windmills. This design has been relatively untouched for centuries. Whether considering the windmills of Holland or the old windmills on the prairies of West Texas, these systems have been the most productive of all. There are essentially two types of HAWT: Upwind and Downwind.

Upwind HAWT
Upwind systems are the most common of the "small wind" market, which is reserved for generators that range in output power of up to 50kW. To face into the wind, these systems incorporate a tail vain, which in many cases, as in our PowerMax+ 20K and PowerMax+ 25K units, automatically adjusts to the angle of the wind to limit overspeed rotation.

Downwind HAWT
Facing away from the wind and without a tail, these systems are usually what appear in large-wind megawatt wind farms.

Practical Explanation:
Simply put, tail-furling and upwind systems lose power during high winds. This decrease in productivity is caused when the blades spin so fast that the oncoming wind meets a "wall of blades" and cannot pass through the blades to create the drag necessary to rotate the shaft with any efficiency. The result is a dramatic reduction on the power curve after the upwind system reaches its peak power. Mimicking the pitching blades of the megawatt turbines, the Talon series from A&C Green Energy reaches its peak power quickly and then maintains the peak output up to 56 mph. In the graph below, the Talon is represented by the BLUE curve, while the RED curve is from a typical upwind system of the "same" rated output. Because of Variable Pitch Technology, the Talon produces higher wattage output at any given wind, reaches its peak power in lower wind and is able to sustain that peak output in higher winds. This increased wattage output means higher energy production. Higher energy production means more energy savings and more money for you. The longer your Talon is in service, the more money you will earn over a similar upwind system.



Technical Explanation:

Quote:

---

When the wind speed is below 7 mph (3m/s), the turbine blade angle remains static and the angle (X1) formed between the blade and turbine plane is B° (X1=B°). This is the ideal angle for the blades to begin their rotation. As long as the wind speed reaches 7 mph, the blades will begin to rotate.

While rotating, the outermost edge of the blade will be driven by the centrifugal force generated by the rotation of the blade to tilt toward the turbine plane. As the wind speed increases, the blade angle (X1) will then decrease to 0° so that the blade is parallel with the turbine plane. At this angle, the turbine has nearly reached its rated output power.

When the wind speed is between 20 mph - 55 mph (9m/s - 25m/s), the blade angle (X1) will stay near 0° with slight fluctuations in order to maintain it’s rated power.

When the wind speed is between 55 mph - 112 mph (25m/s - 50m/s), the wind will draw the blade by the centrifugal force, so the angle (X1) will continue to decrease to a negative angle (X1 = -B°) [B° and -B° are not the same]. Under this negative angle, the blade angle will produce a resistance on the rotation of turbine blades to slow down the turbine, thus protecting it from over speed operation. The maximum rotation of the turbine will be no more than 380 RPM.

---

About Wind Here: Winning with Wind
Wind Here believes that harmony exists in nature everywhere and a dual usage of the land is symbiotic and brings multiple benefits to the community that are compounded beyond the energy solutions of the wind farms alone.

Wind Here plans are in place to introduce economic development stimulus concepts in wind farms and wind parks that will increase rural economies with local job creation and investment opportunities with multiple revenue streams:

Quote:

---

Eco parks: Nature Trails, Camping, Sports and Recreation

Wind Plex: Racing Parks, Amusement Parks, Water Parks, Restaurants, Hospitality, Golf Course, Museum, Shops

Wind Farms: Rural and Remote areas where dual usage is prohibitive beyond grazing livestock or agricultural activities

Windustrial Parks: Industrial and Commercial Green Zones powered by wind turbines

---

Wind Here Wind Farms and Wind Parks are professionally surveyed and site tested prior to installing appropriate wind turbine technology. Wind Here is currently conducting site suitability tests with three Talon 2 wind turbines manufactured by A & C Green Energy. http://www.acgreenenergy.com

Wind Here erects a group of wind turbines in the same location used for production of electric power. Individual turbines are interconnected with a medium voltage (usually 34.5 kV) power collection system and communications network. At a substation, this medium-voltage electrical current is increased in voltage with a transformer for connection to the high voltage transmission system.

A large wind farm may consist of a few dozen to several hundred individual wind turbines, and cover an extended area of hundreds of square miles, but the land between the turbines may be used for agricultural or other purposes. A wind farm may be located on-shore to harvest the inland thermals on hilly slopes and valleys and open plains or off-shore to take advantage of strong winds blowing over the surface of an ocean or lake.




HRTE Management Team

Mark K. Ryun President / CEO
Mark Ryun was appointed as president secretary, treasurer and director of Here Enterprises, Inc. (HRTE) on March 4, 2010. Since July of 1991, Mr. Mark K. Ryun has been the president and chief executive officer of the Coastal Wood Floors, a full-service hardwood flooring contracting company based in Haleiwa, Hawaii. Over the past 18 years, Mr. Ryun has been a member of the board of directors with the Honolulu Board of Contractors in the State of Hawaii, the National Wood Flooring Association (NWFA), and the Better Business Bureau of Hawaii (BBB). Since June of 1992, Mr Ryun raced professional motocross for Pflueger Honda, Montgomery Motors, No Fear and Oakley. He competed in Motocross events for ten years.

In 2000, Mr. Ryun built motocross tracks for Hawaii Motorsports Association, finishing all phases from financially funding the build, designing the course and directing the crew until it was completed. As a leader, Mr. Ryun has demonstrated high standards of integrity in his business operations through personal commitment and a “hands on” involvement in every aspect of the business. Mr. Ryun maintains the corporate vision on a day-to-day basis through a tireless commitment to solid communication at all levels.

George Russell / CFO
George Russell was appointed as Chief Financial Officer of Here Enterprises Inc. (HRTE) on May 6th, 2011. Since 1996, Mr. Russell has acted as investment adviser, financial planner, and retirement consultant for affluent clients, small businesses, and medium capitalization companies. He was presented the Blue Chip Award five consecutive years for excellence in client services. He was certified and performed as a Portfolio Manager of individual equities. In 2006, Mr. Russell was named Managing Director and Controller of a new construction/ remodeling conglomerate operating throughout the state of Texas.

Mr. Russell earned an Executive MBA in Management and Strategy and holds a Bachelor’s degree in Business Administration. He proudly served in the United States Army, and is a highly decorated, combat veteran of Operation Desert Storm.



HRTE Contact Info

Here Enterprises, Inc.
848 North Rainbow Boulevard
Suite 2952
Las Vegas, NV 89107

Phone: 210-957-7879
Website: http://www.windhere.com
Investor Relations
investors@hereenterprises.com

AMBS - Amarantus BioSciences

(image header done by diva)

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc.,(OTCBB: AMBS) formerly Jumpkicks, Inc., is a development-stage biotechnology company. The Company focuses on developing its intellectual property and technology to develop drug candidates to treat human disease. The Company owns the intellectual property rights to a therapeutic protein, the Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF). On May 25, 2011, the Company entered into an Agreement and Plan of Merger with Amarantus Therapeutics, Inc., a privately held Delaware corporation (Amarantus), and Amarantus Therapeutics, Inc., formerly JKIK Acquisition Corp. (Acquisition Sub), which is its newly formed wholly owned Delaware subsidiary. On May 25, 2011, in connection with the closing of this merger transaction, Amarantus merged with and into Amarantus Therapeutics, Inc. (the Merger). The Company focuses to carry on the business of Amarantus as its sole line of business.

Amarantus BioSciences, Inc. is engaged in the research and development of first-in-class disease-modifying treatments that address the underlying cause of cell death, known as apoptosis, associated with a wide range of diseases. The Company's most advanced product candidate,

MANF, is a therapeutic protein indicated for the treatment of Parkinson's disease and Myocardial Infarction. Currently incubating at the Parkinson's Institute in Sunnyvale, CA.

Amarantus BioSciences is the recipient of a research grant from The Michael J. Fox Foundation for Parkinson's Research.

See www.Amarantus.com.

Amarantus BioSciences , a California-based biotechnology company developing a first-in-class anti-apoptosis therapeutic protein known as MANF, and Generex Biotechnology, Inc. (OTCBB: GNBT), a Toronto-based biotechnology company developing an oral-insulin spray technology known as Oral-lyn(TM) currently in Phase III clinical trials, today announced that the companies have selected the development of a MANF-based therapeutic for the treatment of the beta cell destruction at the root of diabetes as the second program for their joint research collaboration announced on May 31, 2011. The first collaboration program announced on June 8, 2011 is for the development of a MANF-based diagnostic test to identify a sub-population at risk of developing Type 1 or Type 2 diabetes.

"Taken together with the MANF-based early diabetes detection diagnostic, the potential therapeutic-diagnostic combination would represent a major step forward in the ability for physicians to manage the health of those persons most at risk of developing diabetes," said Dr. James Anderson, Senior Scientific Advisor and Director of Generex. "The development of a MANF-based therapeutic that would be administered using Generex' proprietary RapidMist(TM) technology, and potentially be used in combination with Oral-lyn(TM), would represent a significant, new competitive advantage over other therapeutic interventions currently being studied and dramatically increase convenience and patient well-being."

"MANF's profile of activity indicates that it has significant potential to impact the beta cell dysfunction at the root of impaired insulin secretion in patients leading to clinical diabetes," said Dr. John Commissiong, Chief Scientific Officer of Amarantus. "MANF's ability to correct protein misfolding and mitigate apoptosis may slow or prevent the progression of patients with beta cell dysfunction into full blown diabetes."

"The partnership with Generex will allow Amarantus to exploit its technologies in the field of diabetes through its wholly-owned subsidiary Amarantus MA," said Martin D. Cleary, Chairman & CEO of Amarantus. "These collaboration programs are a major step toward the validation of the enormous potential of the MANF platform that Amarantus is judiciously advancing for the treatment of the apoptosis associated with a wide range of human disorders, including pre-diabetes and diabetes."

"Given the recent positive preliminary results from our 084 and Prevoral trials with Oral-lyn(TM), we now believe we better understand the best use for our Oral-lyn(TM) product and feel it is appropriate to plan for a partnership that will add ground-breaking scientific research to support Generex's future pipeline of diabetes product candidates," said Dr. Gerald Bernstein, Vice President of Medical Affairs for Generex Biotechnology. "Today's announcement affirms our commitment to the potential of our RapidMist(TM) technology to successfully deliver protein drug candidates to treat diabetes."

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's buccal insulin spray product, Generex Oral-lyn(TM) is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen E

xpress has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Scientific Publications

PhenoGuard Protein Discovery Engine

1. Takeshima T, Johnston JM, Commissiong JW (1994) Mesencephalic type-1 astrocytes rescue dopaminergic neurons from death induced by derum-deprivation. J Neurosci 14: 4769-4779
2. Panchision D., Martin-DeLeon P, Takeshima T, Johnston J, Shimoda K, Tsoulfas P, McKay R, Commissiong JW (1998). An immortalized Type-1 Astrocyte Origin of a Dopaminergic Neurotrophic Factor. J Mol Neurosci. 11-208-221
3. Takeshima T., Shimoda K. Johnston J.M., Commissiong J. (1996). Standard methods to bioassay neurotrophic factors for dopaminergic neurons. J Neurosci Meth 67: 27-41

MANF

1. Hellman U, Arumäe U, Yu L, Lindholm P, Peränen J, Saarma M, Permi P (2011) Mesencephalic astrocyte-derived neurotrophic factor (MANF) has a unique mechanism to rescue apoptotic neurons . J Biol Chem 286:2675-2680.
2. Glembotski CC (2010) Functions for the cardiomyokine, MANF, in cardioprotection, hypertrophy and heart failure. J Mol Cell Cardiology, In Press
3. Hellman U, Peränen J, Saarma M, Permpanich B (2010) (1)H, (13)C and (15)N resonance assignments of the human mesencephalic astrocyte-derived neurotrophic factor. Biomol NMR Assign 4:215-217.
4. Airavaara M, Chiocco MJ, Howard DB, Zuchowski KL, Peränen J, Liu C, Fang S, Hoffer BJ, Wang Y, Harvey CA (2010) Widespread cortical expression of MANF by AAV serotype 7: Localization and protection against ischemic brain injury. Exp Neurol 225:104-113.
5. Lindholm P, Saarma M (2010) Novel CDNF/MANF Family of Neurotrophic Factors. Dev Neurobiol 70:360-371.
6. Voutilainen M, Back S, Porsti E., Toppinen L, Lindgren L, Lindholm P, Peranen J, Saarma M and Tuominen R (2009). Mesencephalic Astrocyte-derived Neurotrophic Factor is Neurorestorative in a Rat Model of Parkinson’s Disease. J Neurosci, July 29, 2009. 29(30):9651–9659.
7. Yong-Qiang Yu1, Lian-Cheng Liu1, Fa-Cai Wang2, Yan Liang2, Da-Qin Cha2, Jing-Jing Zhang2, Yu-Jun Shen2, Hai-Ping Wang2, Shengyun Fang2,3 and Yu-Xian Shen2 (2009). Induction profile of MANF/ARMET by cerebral ischemia and its implication for neuron protection, J CBFM Sept 23: 1–13
8. Airavaara M, Shen H, Kuo C-C, Peränen J, Saarma M, Hoffer B, Wang Y (2009) Mesencephalic astrocyte-derived neurotrophic factor reduces ischemic brain injury and promotes behavioral recovery in rats. J Comp Neurol 515: 116-124.
9. Parkash V, Lindholm P, Peranen J, Kalkkinen N, Oksanen E, Saarma M, Leppanen VM, Goldman A (2009). The structure of the conserved neurotrophic factors MANF and CDNF explains why they are bifunctional. Protein Engineering Design Selection 22: 233-24.
10. Palgia M, Lindstrom R, Peranen J, T. Piepponen P, Saarma M, Tapio I. Heino TI (2009) Evidence that DmMANF is an invertebrate neurotrophic factor supporting dopaminergic neurons. PNAS 106: 2429–2434.
11. Tadimalla A, Belmont PJ, Thuerauf DJ, Glassy MS, Martindale JJ, Gude N, Sussman MA, Glembotski CC (2008) Mesencephalic Astrocyte-Derived Neurotrophic Factor Is an Ischemia-Inducible Secreted Endoplasmic Reticulum Stress Response Protein in the Heart. Cir Res 103: 1249-1258.
12. Lindholm P, Andressoo J-O, Kalkkinen N, Kokaia Z, Lindvall O, Timmusk T, Peranen J, Saarma M (2008). MANF is widely expressed in mammalian tissues and differently regulated after ischemic and epileptic insults in rodent brain. Mol Cell Neurosci 39: 356-371
13. Apostolou A, Shen Y, Liang Y, Lou Y, Fang S. (2008) Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death. Exp Cell Res 14: 2454-2467.
14. Mizobuchi N, Hoseki J, Kubota H, Toyokuni Y, Nozaki K, Naitoh M, Koizumi A, Nagata K. (2007) ARMET is a Soluble ER Protein Induced by the Unfolded Protein Response via ERSE-II Element. Cell Struct Funct 32: 41-50.
15. Zhou C, Xiao C, Commissiong JW, Krnjevic K, Ye JH. (2006) Mesencephalic astrocyte-derived neurotrophic factor enhances nigral [gamma]-aminobutyric acid release. NeuroReport 17: 293-297.
16. Petrova PS, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire A, Shridhar V, Smith DI, Kelly J, Durocher Y, Commissiong JW. (2004) Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases. Prog Brain Res 146: 168-183.
17. Petrova PS, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire AE, Shridhar V, Smith DI, Kelly J, Durocher Y, Commissiong JW. (2003) MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 20: 173-188.

Management Team

Gerald E. Commissiong

President & CEO

Mr. Commissiong was appointed President & CEO of Amarantus BioSciences in October 2011. In March 2011, Mr. Commissiong was promoted to Chief Operating Officer of Amarantus, where his duties included strategic transactions, licensing, research collaborations, mergers & acquisitions, fund raising and investor relations. From August 2009 until March 2011, he served as Chief Business Officer where he was responsible for business development and corporate development. In 2008, Mr. Commissiong co-founded Amarantus with Dr. John Commissiong PhD and served as its President & CEO until August 2009. In that timeframe, Mr. Commissiong attracted seed capital, acquired the intellectual property rights to MANF and recruited scientific and executive talent to Amarantus to allow for the further development of the technologies. Mr. Commissiong has served as a Director of Amarantus since 2008. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus Financial Decisions from Stanford University.

John W. Commissiong, PhD

Chief Scientific Officer

Dr. Commissiong has served as the Chief Scientific Officer and a Director of Amarantus since co-founding the company in 2009. From 2000 through 2008 Dr. Commissiong served as the CSO of Neurotrophics Inc & Prescient Neuropharma Inc. Dr. Commissiong has been focused on the discovery of novel neurotrophic factors for the treatment of neurodegenerative diseases as well as understanding the fundamental underlying biology of protoplasmic type-1 astrocytes that secrete neurotrophic factors. He was Chief of the Neural Transplantation Unit, NINDS-NIH, from 1989-94 where his research focused on identifying therapeutic approaches to spinal cord injury. Dr. Commissiong was Head of the Neurotrophic Factors Group, NINDS-NIH, from 1994-97 where he focused on developing technologies to systematically identify novel neurotrophic factors with applications for specific Central Nervous System disorders. He co-founded Prescient Neuropharma in 1999, and discovered MANF in 2003. MANF is currently in preclinical development for the treatment of Parkinson’s disease. The work pioneered by Dr. Commissiong has led to significant advancements in the field of astrocyte-neuron biology. Dr. Commissiong believes that a fundamental understanding of astrocyte-neuron interactions in the Central Nervous System will lead to a new generation of therapies to treat brain-related disorders.

Dr. Commissiong did his Postdoctoral work in the Lab Preclin Pharmac, NIMH-NIH, concentrating on the application of quadrupole mass spectrometry in the analysis of neurotransmitters. He holds a Ph.D. in Neurophysiology from the University of Southampton, an M.Sc. in Biochemical Pharmacology from the University of Southampton, and a B.S. in Biology and Chemistry from the University of the West Indies.

Marc E. Faerber

Controller / Chief Financial Officer Controller

Mr. Faerber has over thirty years of experience and over nineteen of those in life sciences. His experience has spanned Fortune 500 companies to start-ups, and everything in between. During the past ten years Mr. Faerber has been providing financial, business and advisory services to a broad base of start-up companies primarily in the fields of cardiology, gastroenterology, orthopedics, diagnostics and biotechnology.

Mr. Faerber has extensive transactional experience, including considerable experience in establishing international organizations throughout Europe and parts of Asia, international technology licensing and distribution transactions, mergers and acquisitions, and numerous funding transactions, including an initial public offering as well as other international business structural issues. During Mr. Faerber’s career he has held various positions in finance and corporate management including CFO, CEO and Director. Mr. Faerber started his career working for KPMG, is a certified public accountant, and has a Bachelor of Sciences in Business Administration from Providence College.

Contact Us

Amarantus BioSciences, Inc.

c/o The Parkinson’s Institute

675 Almanor Ave.

Sunnyvale, CA 94085

info@amarantus.com

Ph: (408) 737-2734

Fax: (408) 852-4427

BEFORE THERE WAS TEQUILA~There was VUQO~Due Diligence

BEFORE THERE WAS TEQUILA~There was VUQO~Due Diligence

BEFORE THERE WAS TEQUILA, THERE WAS VUQO

The history of VuQo Premium Vodka dates back at least four centuries. VuQo Premium Vodka is based on an ancient technology practiced in the Philippines long before the Spanish conquistadores set foot on its shores.

It is the same technology that Filipino seafarers brought to Mexico through the Spanish Galleon trades to create the now popular tequila. Coconut vodka was the drink in those ancient times, on those far eastern shores. It was, in a manner of speaking, a tribal drink, one that sealed brotherhoods and with which the day's bounty was enjoyed and shared. It is this spirit that VuQo Premium Vodka hopes to recreate and celebrate today.

VuQo Holdings Corp. is a publicly owned corporation, and through its subsidiaries, the company engages in developing, producing, distilling, bottling, packaging, distributing, and marketing wines and spirits.

The company offers VuQo Premium Vodka, the only vodka in the world distilled from coconut nectar. VuQo (40 alcohol by volume) is continuously distilled and filtered multiple times, and is packaged in an elegantly designed frosted bottle. Currently, VuQo is distributed in the United States in California, Texas, and Georgia, as well as Guam and the Philippines.

VuQo also owns the brand Haliya Light Fruit Wines, which are wines handcrafted in small batches using fruits that thrive in the Philippines. Haliya is available in two variants: Mango Wine (13 alcohol-by-volume) and Black Plum Wine (12 ). Both are packaged in traditional wine bottles with award-winning label designs. Haliya is currently distributed in the Philippines, Guam, and the United States.



Security Details
VuQo Holdings Corp. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, “VUQO”, and within the OTC PINK limited market tier. As such, Business, operational and financial information on VUQO is fully transparent and available to public view.

Visit http://www.otcmarkets.com/stock/VUQO/quote for more information.

Market Value1 $6,513,107 a/o Sep 15, 2011
Shares Outstanding 54,275,891 a/o May 04, 2011
Float 8,860,000 a/o Apr 21, 2011
Authorized Shares 100,000,000 a/o Dec 31, 2010
Par Value 0.001

Transfer Agent
American Registrar & Transfer Co
342 East 900 South
Salt Lake City, UT, 84111
801-363-9065

Last FORM 10Q
http://www.otcmarkets.com/otciq/ajax/showFinancialReportById.pdf?id=49747

Shareholders of Record 300 a/o Dec 31, 2009
Employees 109 a/o Feb 12, 2009
Incorporated In: NY, USA
Year of Inc.: 2006

Security Notes
Formerly=Bona Coffee Holdings Corp. until 5-2011
Formerly=Espo's Surf & Sport, Inc. until 8-2008

Sector: 2080-Beverages

Source: otcmarkets.com and yahoo financial



Products & Services

VuQo Premium Vodka

VuQo Premium Vodka is made of coconut nectar, unlike traditional vodkas distilled from wheat or potatoes.

The core ingredient that makes VuQo comes from Philippine coconut trees - the best in the world grown on the country's nutrient-rich volcanic soil and tropical climate.

The healthy coconut trees produce coconut flowers thirty feet above the ground. The flower is cut, and every morning so its sweet coconut liquid is collected and readied for fermentation and distillation to create a vodka of utmost quality.
The history of VuQo Premium Vodka dates back at least four centuries. VuQo Premium Vodka is based on an ancient technology practiced in the Philippines long before Spanish conquistadores set foot on its shores.

It is the same technology that Filipino seafarers brought to Mexico through the Spanish Galleon trades to create the now popular tequila. Coconut vodka was the drink in those ancient times, on those far eastern shores. It was, in a manner of speaking, a tribal drink, one that sealed brotherhoods and with which the day's bounty was enjoyed and shared. It is this spirit that VuQo Premium Vodka hopes to recreate and celebrate today.
VuQo Premium Vodka is the only true coconut vodka, as it is distilled from coconut nectar and not just infused with coconut flavor.

After the finest coconut nectar has been selected and fermented, it is distilled multiple times, cleansing it of all impurities. The product is then blended with water and sent through a series of activated carbon filters. The end result is pure perfection.

Distributors:

American Importing

We are Wine, Spirits & Beer distributors in the New Jersey & New York market area. Our mission is to bring the finest alcohol products to the best retailers in the market who provide the end consumer with quality service and product knowledge. Please browse our online catalog to find a detailed listing of all of our products offered for sale in New Jersey and specifically our wine products that are now available for sale in New York.
American Importing Exporting in Brick, NJ is a private company categorized under Wholesale Liquors. Current estimates show this company has an annual revenue of $10 to 20 million

http://www.manta.com/c/mtwvltg/american-importing-exporting

AmericanImporting.com

Pacific Edge Wine & Spirits
Pacific Edge Wine & Spirits in Agoura Hills, CA is a private company categorized under Wholesale Liquors. Our records show it was established in 2002 and incorporated in California. Current estimates show this company has an annual revenue of $500,000 to $1 million.

http://www.manta.com/c/mm2wgb8/pacific-edge-wine-spirit
http://www.pacificedgesales.com

http://www.pacificedgesales.com/suppliers.html

Other Links:

http://www.vuqo.com/

http://haliyawines.multiply.com/

http://twitter.com/#!/VuQoVodka

http://www.myspace.com/vuqo

http://www.facebook.com/HaliyaLightFruitWines

http://www.youtube.com/vuqovodka



VuQo Articles:

From Buko to VuQo http://buko2vuqo.wordpress.com/

Golden Harvest http://www.vuqo.com/articles/bluprint-magazine-may-2010-issue

VuQo and Filipino Flash Team Up! http://www.bakitwhy.com/articles/vuqo-and-filipino-flash-team

Entrepreneur Magazine http://www.vuqo.com/articles/entrepreneur-magazine

VuQo Signs Boxing Champ Nonito Donaire Jr. http://insidesports.ph/boxing/vuqo-signs-boxing-champ-nonito-donaire-jr/

Top=Shelf Lambanog Makes U.S Debut http://www.abs-cbnnews.com/pinoy-migration/balitang-america/06/03/09/top-shelf-lambanog-makes-us-debut



Management

Richard O. Cabael, Chief Executive Officer (CEO)

Mr. Cabael is the founder/creator of VuQo Premium Vodka, the first vodka distilled from coconut.
He brings over 16 years of experience as a sales professional and company executive, including
the last ten years in the liquor industry. His expertise in sales, management, two and three-tier
distribution, and managing product channels comes from working with start-ups, mid-size, and
Fortune 500 companies. Mr. Cabael has held positions in Philips Electronics, Autoweb.Com, and
most recently, The Margarita King, of which he was Vice President of Sales

more info http://www.linkedin.com/in/richcabael

CEO Interview

Felicitas Q. Garcia, Chief Financial Officer (CFO)

Ms. Garcia brings over 25 years of experience as an accounting professional. She earned her
license as a Certified Public Accountant in 1982. Prior to joining VuQo, she was the accounting
manager of Himlayang Pilipino Plans, SPP Inc., AMA Plans Inc., and the chief accountant of the
Vazquez-Madrigal group of companies. Ms. Garcia was also an accounting instructor at the Tech.
Institute of the Philippines.


Contact Info

230 Park Avenue
New York City, NY 10169
Website: http://www.vuqo.com
Phone: 1-888-536-1431
Email: info@vuqo.com

Visit on twitter: http://twitter.com/#!/vuqovodka


As Always: Our Number 1 Priority is to educate. Penny stocks are very volatile, Always do your own Due Diligence